Johnson & Johnson Family of Companies
NEWS
As news continues about Johnson & Johnson’s talcum powder containing carcinogenic asbestos, more than 100 drug inspectors in India are seizing samples, characterized The Times of India. The company, however, downplays that description, suggesting that the samples are fairly routine.
A Reuters analysis of company documents reveals that Johnson & Johnson knew about levels of asbestos contamination in its talc products, but did not report it to the FDA.
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
Tremfya was being compared to Novartis’ Cosentyx (secukinumab) in a head-to-head study. In the trial, Tremfya showed that 84.5 percent of patients treated with the drug achieved at least 90 percent improvement in their baseline Psoriasis Area Severity Index (PASI) score at 48 weeks.
With the closure of another year just weeks ahead, this time of year is one that many people use to take a look behind and see what lessons were learned over the past 12 months. For the world of biopharma, it’s also important to see what lessons have been learned.
The government alleged Actelion provided money to a nonprofit to cover copay costs for Medicare drugs, a violation of the False Claims Act.
While Xarelto failed to show statistical significance, Janssen said there was a clinically meaningful 60 percent reduction of VTE events compared to placebo during times of treatment.
Janssen Pharmaceutical, a Johnson & Johnson company, along with Legend Biotech, reported results from their LEGEND-2 Phase I/II clinical trial of CAR-T therapy LCAR-B38M. The therapeutic was being investigated in patients with advanced relapsed or refractory (r/r) multiple myeloma.
Argenx, based in Ghent, Belgium, announced a global collaboration and license deal with Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson.
JOBS
IN THE PRESS